Skip to content
Publicly Available Published by De Gruyter May 19, 2014

Helmut Buschmann is Awarded the 2014 IUPAC-Richter Prize

From the journal Chemistry International

The 2014 IUPAC-Richter Prize in Medicinal Chemistry has been awarded to Dr. Helmut Buschmann. Dr. Buschmann received this award in recognition of his outstanding creative contributions to the invention, discovery and development of the novel analgesic drug tapentadol (Nucynta™, Palexia™), first approved in 2008.

The IUPAC-Richter Prize, comprising a plaque and a check for USD 10000, will be presented on 7-11 September 2014 at the 23rd European Federation of Medicinal Chemistry International Symposium in Lisbon, Portugal. Dr. Buschmann will present a lecture at this Symposium and also, on 21 May 2014, at the American Chemical Society’s 34th National Medicinal Symposium in Charleston, South Carolina, USA.

Helmut Buschmann studied chemistry at the Rheinisch-Westfälische Technische Hochschule (RWTH), Aachen, Germany and also obtained his PhD there, in organic synthesis, with Professor Hans-Dieter Scharf. He started his career in pharmaceutical research in 1992 at Grünenthal GmbH, Aachen, becoming Head of the Department of Synthetic Chemistry in 1996, and then, in 2001, Head of Chemical Research.

From 2002 to 2008 he was Research Director of Laboratories for Dr. Esteve, in Barcelona. Since then he has been teaching medicinal chemistry at the University of Rostock and at the RWTH Aachen. He is also a member of Pharma Consulting Aachen and is Chief Scientific Officer of Savira Pharmaceuticals GmbH.

Gedeon Richter Plc., founded in 1901 and headquartered in Budapest, Hungary, is a major pharmaceutical company in Central Eastern Europe, with an expanding direct presence in Western Europe. Richter’s consolidated sales were approximately EUR 1.1 billion (USD 1.5 billion) while its market capitalization amounted to EUR 2.3 billion (USD 3.1 billion) in 2012. The product portfolio of the company covers important therapeutic areas, including gynecology, central nervous system and cardiovascular. Having the largest R&D unit in Central Eastern Europe, the company’s original research activity focuses on CNS disorders. With its widely acknowledged steroid chemistry expertise, Richter is a significant player in the female healthcare field worldwide. Richter is also active in the scope of biosimilar product development.

More information about Gedeon Richter Plc. and its activities is available at .

Online erschienen: 2014-5-19
Erschienen im Druck: 2014-5-1

©2014 by Walter de Gruyter GmbH & Co.

Downloaded on 2.3.2024 from
Scroll to top button